Cytek Biosciences (CTKB) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 10, 2026, to be held virtually, with voting on director elections, executive compensation, and auditor ratification.

• Only stockholders of record as of April 13, 2026, are entitled to vote, with 129,142,587 shares outstanding.

• Proxy materials are available online, and voting can be done via internet, phone, or mail until June 9, 2026.

Voting matters and shareholder proposals

• Three Class II directors (Vera Imper, Ph.D., Glenn P. Muir, Ming Yan, Ph.D.) are nominated for three-year terms expiring at the 2029 annual meeting.

• Advisory vote on executive compensation for the year ended December 31, 2025.

• Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.

• Shareholder proposals for the 2027 meeting must be submitted by December 29, 2026, for inclusion in proxy materials.

Board of directors and corporate governance

• The board consists of seven members, with a classified structure and majority independence per Nasdaq standards.

• Dr. Jiang serves as CEO and board chair; Deborah Neff is lead independent director.

• Board committees include Audit, Compensation, and Nominating and Corporate Governance, all with independent members.

• Annual board and committee performance assessments are conducted.

• Stockholder engagement efforts addressed concerns about internal controls and governance, leading to remediation of material weaknesses.